Cybin Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYBN American 8731 https://www.cybin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cybin Inc

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses - Nov 30th, 2023 12:30 pm
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City - Nov 20th, 2023 12:30 pm
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 - Nov 16th, 2023 12:30 pm
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting - Nov 15th, 2023 12:30 pm
Cybin Reports Second Quarter Financial Results and Recent Business Highlights - Nov 15th, 2023 12:16 am
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders - Nov 14th, 2023 6:00 pm
Cybin Announces up to US$64 Million Offering of Units - Nov 10th, 2023 1:03 pm
Cybin to Participate at the 2023 Milken Institute Future of Health Summit - Nov 3rd, 2023 11:40 am
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 - Nov 1st, 2023 7:32 pm
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline - Nov 1st, 2023 11:30 am
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 - Oct 31st, 2023 1:00 pm
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Oct 31st, 2023 11:45 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Oct 29th, 2023 9:17 pm
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs - Oct 26th, 2023 11:30 am
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program - Oct 25th, 2023 11:30 am
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics - Oct 23rd, 2023 11:33 am
Small Pharma Obtains Final Order Approving Arrangement - Oct 17th, 2023 9:35 pm
Cybin Announces Results of Annual and Special Meeting of Shareholders - Oct 12th, 2023 9:00 pm
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit - Oct 6th, 2023 11:30 am
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit - Oct 4th, 2023 11:30 am